Cargando…
Emerging antiplatelet agents, differential pharmacology, and clinical utility
The aspirin–clopidogrel combination is the current gold standard antiplatelet regimen following percutaneous coronary intervention and for the treatment of acute coronary syndrome. Despite the clinical benefit of this combination, patients continue to have vascular events. Another purinergic (P2Y(12...
Autores principales: | Das, Pranab, Oliphant, Carrie S, Beach, Elizabeth, Thapa, Rashmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262324/ https://www.ncbi.nlm.nih.gov/pubmed/22282687 |
Ejemplares similares
-
Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013) -
Peripheral interventions and antiplatelet therapy: Role in current practice
por: Singh, Pahul, et al.
Publicado: (2017) -
Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014) -
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol
por: Malerba, Mario, et al.
Publicado: (2014) -
Newer agents in antiplatelet therapy: a review
por: Yeung, Jennifer, et al.
Publicado: (2012)